Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

41.49
Delayed Data
As of Jul 27
 -0.50 / -1.19%
Today’s Change
30.89
Today|||52-Week Range
57.41
+15.70%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$79.5B

Company Description

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas. The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085

Employees

Shareholders

Other institutional6.65%
Mutual fund holders1.67%
Individual stakeholders--

Top Executives

Lars Fruergaard JørgensenPresident & Chief Executive Officer
Jesper BrandgaardChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Mads KrogsgaardChief Science Officer
Lars GreenExecutive VP & Head-Business Services & Compliance